Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

被引：37
|
作者：
Curigliano, Giuseppe [1 ,2 ]
Hu, Xichun [3 ]
Dent, Rebecca Alexandra [4 ]
Yonemori, Kan [5 ]
Barrios Sr, Carlos H. [6 ]
O'Shaughnessy, Joyce [7 ]
Wildiers, Hans [8 ]
Zhang, Qingyuan [9 ]
Im, Seock-Ah [10 ]
Saura, Cristina [11 ]
Biganzoli, Laura [12 ]
Sohn, Joohyuk [13 ]
Levy, Christelle [14 ]
Jacot, William [15 ]
Begbie, Natasha [16 ]
Ke, Jun [17 ]
Patel, Gargi Surendra [18 ]
Bardia, Aditya
机构：
[1] Univ Milan, Milan, Italy
[2] IRCCS, European Inst Oncol, Milan, Italy
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[5] Natl Canc Ctr, Tokyo, Japan
[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[7] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA
[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium
[9] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[11] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[12] Santo Stefano Hosp, Azienda USL Toscana Ctr, Dept Oncol, Prato, Italy
[13] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[14] Ctr Francois Baclesse, Caen, France
[15] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France
[16] AstraZeneca, Clin Dev, Late Stage Dev, Oncol R&D, Cambridge, England
[17] AstraZeneca, Biometr Oncol, Late Stage Dev, Oncol R&D, Waltham, MA USA
[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.17_suppl.LBA1000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1000
引用
收藏
页码：LBA1000 / LBA1000
页数：1
相关论文
共 50 条
  • [41] Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
    Hua, Xin
    Bi, Xi-Wen
    Zhao, Jian-Li
    Shi, Yan-Xia
    Lin, Ying
    Wu, Zhi-Yong
    Zhang, Yuan-Qi
    Zhang, Le-Hong
    Zhang, An-Qing
    Huang, Heng
    Liu, Xin-Mei
    Xu, Fei
    Guo, Ying
    Xia, Wen
    Hong, Ruo-Xi
    Jiang, Kui-Kui
    Xue, Cong
    An, Xin
    Zhong, Yong-Yi
    Wang, Shu-Sen
    Huang, Jia-Jia
    Yuan, Zhong-Yu
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 637 - 645
  • [42] Real-world treatment durations without chemotherapy (CT) for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)
    Swallow, Elyse
    Wang, Jenny
    Thomason, Darren
    Tan, Ruo-Ding
    Kageleiry, Andrew
    Signorovitch, James
    CANCER RESEARCH, 2015, 75
  • [43] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2e) breast cancer (BC): Results from TROPION-Breast01 China cohort
    Wang, S.
    Zhang, Q.
    Jiang, Z.
    Tong, Z.
    Li, W.
    Wang, J.
    Ouyang, Q.
    Yao, T.
    Wang, Y.
    Sun, M. L.
    Wang, X.
    Wang, S.
    Zang, A.
    Zhang, Z.
    Chen, W.
    Wang, X.
    Li, H.
    Sheng, Y.
    Bardia, A.
    Xu, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1418 - S1419
  • [44] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
    Luis, Ines Maria Vaz Duarte
    Guo, Hao
    Barry, William Thomas
    Krop, Ian E.
    Wagle, Nikhil
    Lowe, Alarice
    Gore, Danielle
    Andrews, Chelsea
    Osmani, Wafa
    Isakoff, Steven J.
    Tung, Nadine M.
    Winer, Eric P.
    Lin, Nancy U.
    Freedman, Rachel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)
    Hamilton, Erika
    Jhaveri, Komal
    Loi, Sherene
    Anders, Carey
    Schmid, Peter
    Penkov, Konstantin
    Artamonova, Elena
    Zhukova, Lyudmila
    Stroyakovsky, Daniil L.
    Doval, Dinesh Chandra
    Villanueva, Rafael
    Michelini, Flavia
    Chandarlapaty, Sarat
    Wilson, Matt
    Boston, Sarice R.
    Konpa, Adam
    Mondal, Shoubhik
    Andre, Fabrice
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
    Hurvitz, Sara
    Kim, Sung-Bae
    Chung, Wei-Pang
    Im, Seock-Ah
    Park, Yeon Hee
    Hegg, Roberto
    Kim, Min-Hwan
    Tseng, Ling-Ming
    Petry, Vanessa
    Chung, Chi-Feng
    Iwata, Hiroji
    Hamilton, Erika
    Curigliano, Giuseppe
    Xu, Binghe
    Lee, Caleb
    Liu, Yali
    Cathcart, Jillian
    Bako, Emarjola
    Verma, Sunil
    Cortes, Javier
    CANCER RESEARCH, 2022, 82 (04)
  • [47] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
    Slamon, Dennis J.
    Fasching, Peter A.
    Patel, Ravindranath
    Verma, Sunil
    Hurvitz, Sara A.
    Chia, Stephen K. L.
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Spera, Gonzalo
    Lopez, Celine
    Hor, Ines
    Pelov, Diana
    Hughes, Gareth
    Nawinne, Moditha
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Trends in the choice of first line treatment for hormone - responsive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.
    D'Alonzo, Alessia
    Bighin, Claudia
    Puglisi, Fabio
    DeLaurentiis, Michelino
    Fontana, Andrea
    Pugliese, Palma
    Arpino, Grazia
    Poggio, Francesca
    Vaglica, Marina
    Dellepiane, Chiara
    Blondeaux, Eva
    Conte, Benedetta
    Cognetti, Francesco
    Garrone, Ornella
    Pastorino, Simona
    Ceppi, Marcello
    Del Mastro, Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
    Ciruelos, E. M.
    Garcia, A. A.
    Cortes, J.
    Pernas Simon, S.
    Garate, E.
    Mele, M.
    Montano, A.
    Martinez-Janez, N.
    Oliveira, M.
    de la Haba-Rodriguez, J.
    Vega, E.
    Perello Martorell, A.
    Bermejo De Las Heras, B.
    Cantos Sanchez De Ibarguen, B.
    Martinez, E.
    Vila Navarro, E.
    Pascual, T.
    Gonzalez-Farre, X.
    Villagrasa, P.
    Prat, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S77 - S77
  • [50] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
12345